Ebixa is used to treat patients with moderate to severe Alzheimer’s disease. Alzheimer’s disease is a type of dementia (a brain disorder) that gradually affects memory, intellectual ability and behaviour. The medicine can only be obtained with a prescription. How is Ebixa used?

Ebixa: Ebixa, brand name of Memantine, is a NMDA receptor antagonist medication used to treat people with moderate-to-severe Alzheimer's disease

Memantine (marketed as Ebixa) is the newest drug treatment currently available in the UK for the treatment of Alzheimer’s disease. The others are called donepezil hydrochloride (common brand name Aricept), rivastigmine (common brand name Exelon) and galantamine hydrobromide (common brand name Reminyl) – see information sheets 11, 14 and 17.

Ebixa is a medicine that contains the active substance memantine hydrochloride. It is available as tablets (5 mg, 10 mg, 15 mg and 20 mg). Ebixa is also available as an oral solution, which is supplied with a pump that delivers 5 mg memantine hydrochloride with …

Ebixa is a medicine that contains the active substance memantine hydrochloride. It is available as tablets (5 mg, 10 mg, 15 mg and 20 mg). Ebixa is also available as an oral solution, which is supplied with a pump that delivers 5 mg memantine hydrochloride with …

2023年6月26日 · Ebixa should be administered orally once a day and should be taken at the same time every day. The film-coated tablets can be taken with or without food. Caution is recommended in patients with epilepsy, former history of convulsions or patients with predisposing factors for epilepsy.

2025年1月7日 · Ebixa is used for the treatment of all froms of dementia of the Alzheimer's type. Ebixa may also be used for other types of dementia.

Ebixa belongs to a group of medicines called NMDA-receptor antagonists. Ebixa acts on these NMDA-receptors improving the transmission of nerve signals and the memory. Ebixa is used for the treatment of patients with moderate to severe Alzheimer’s di­sease.

2016年7月8日 · Study Outcome Measures: In each study, the efficacy of Ebixa was evaluated using validated assessments for patients with moderate to severe dementia in a dual outcome strategy that

Moderate to severe Alzheimer's disease. Adult Initially 5 mg daily on the 1st wk, 10 mg daily on the 2nd wk, then 15 mg daily on the 3rd wk. Continue treatment from 4th wk thereafter w/ maintenance dose: 20 mg daily. Max: 20 mg once daily. Elderly >65 yr 20 mg daily.